

Sedana Medical - A blow to the share but relatively non-affecting the case

Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sedana Medical. Our estimate changes do not affect our US estimates, which make up a large chunk of the fundamental value. Hence, we only make small changes to our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Sedana Medical - A blow to the share but relatively non-affecting the case